0.00Open0.65Pre Close0 Volume15 Open Interest11.00Strike Price0.00Turnover96.73%IV8.64%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type-0.3163Delta0.5021Gamma75.53Leverage Ratio-0.0964Theta-0.0002Rho-23.89Eff Leverage0.0026Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet